Dupixent Lawsuit in Mississippi - Free Case Review

Free Case Review

Start Your Free Review

Answer 2-3 quick questions to review your potential case.

Key Takeaway

Mississippi has historically been one of the most plaintiff-friendly states in pharmaceutical litigation, though tort reform legislation in the early 2000s modified venue selection and other procedural rules. An estimated 22,000 Mississippi residents have been prescribed Dupixent since 2017, with prescribing concentrated through the University of Mississippi Medical Center in Jackson, the state's only academic medical center and NCI Community Oncology Research Program site. Mississippi's pure comparative fault system — allowing recovery regardless of plaintiff fault percentage — is plaintiff-favorable. The state's 3-year SOL provides adequate time, and Mississippi's jury pools, particularly in the Southern District and state courts in the Jackson and Delta regions, have shown willingness to hold pharmaceutical companies accountable. Mississippi's large African American population has disproportionately high rates of severe atopic dermatitis, potentially increasing Dupixent prescribing and CTCL exposure in this demographic.

Written By

People's Justice Legal Research Team

Statute of Limitations

Mississippi: 3 years for product liability (Miss. Code Ann. § 15-1-49). Discovery rule applies — the limitations period begins when the plaintiff discovers or should have discovered the injury.

3 years from discovery of injury

Filing Venue

Where to File in Mississippi

Mississippi has two federal judicial districts: the Northern District (Oxford/Aberdeen) and Southern District (Jackson/Gulfport/Hattiesburg). Mississippi follows a pure comparative fault system and does not cap compensatory damages in product liability cases. Mississippi's tort reform legislation has modified some procedural aspects of mass tort cases, including venue selection rules.

Mississippi Data

Exposure in Mississippi

Source: IQVIA prescription data estimates

Source: UMMC / NCI Community Oncology Research Program

Source: Miss. Code Ann. § 11-7-15

FAQ

Frequently Asked Questions

See details below.

Back to Dupixent Lawsuit Lawsuit Overview